menu
    • menu
    [{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Bluestem Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"CSF-1","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Bluestem Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Bluestem Capital"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CSF-1","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Orasis Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Orasis Pharmaceuticals \/ Arboretum Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Orasis Pharmaceuticals \/ Arboretum Ventures"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Optus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Pilocarpine Hydrochloride","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Orasis Pharmaceuticals

    Menu

    Orasis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Optus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Orasis Pharmaceuticals and Optus Partner to Commercialize Qlosi™ in Korea

                            Details : Under the license agreement, Orasis grants Optus the rights to commercialize, import and sell Qlosi (pilocarpine hcl), a novel corrective eye drop for the treatment of presbyopia in adults, in Korea.

                            Brand Name : Qlosi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2024

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Optus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Arboretum Ventures

                            Deal Size : $78.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Orasis Pharmaceuticals Raises $78M to Launch Qlosi™ For Eye Treatment

                            Details : The proceeds will be used to support commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution), a novel corrective eye drop for the treatment of presbyopia in adults.

                            Brand Name : Qlosi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 08, 2024

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Arboretum Ventures

                            Deal Size : $78.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia

                            Details : CSF-1 is a preservative-free formulation of low-dose pilocarpine, a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. It is being investigated for the treatment of pres...

                            Brand Name : CSF-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2023

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candi...

                            Details : Two presentations on Phase 2b clinical trial show CSF-1 met primary endpoints and achieved statistically significant and clinically meaningful improvements in distance-corrected near visual acuity (DCNVA) for participants with presbyopia.

                            Brand Name : CSF-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 23, 2022

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSF-1

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate

                            Details : By repurposing existing and well-studied molecules, CSF-1 is designed to be effective, safe, comfortable, and easy-to-use, corrective eye drop for the treatment of presbyopia as an alternative to reading glasses.

                            Brand Name : CSF-1

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : CSF-1

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed

                            Orasis Pharmaceuticals

                            Israel arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CSF-1

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Bluestem Capital

                            Deal Size : $30.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

                            Details : Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.

                            Brand Name : PresbiDrops

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 10, 2020

                            Lead Product(s) : CSF-1

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Bluestem Capital

                            Deal Size : $30.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth